iCo Therapeutics (iCo Therapeutics) FCF Margin % : 0.00% (As of Mar. 2021)

View and export this data going back to 2009. Start your Free Trial

What is iCo Therapeutics FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. iCo Therapeutics's Free Cash Flow for the three months ended in Mar. 2021 was $0.22 Mil. iCo Therapeutics's Revenue for the three months ended in Mar. 2021 was $0.00 Mil. Therefore, iCo Therapeutics's FCF Margin % for the quarter that ended in Mar. 2021 was 0.00%.

As of today, iCo Therapeutics's current FCF Yield % is -0.61%.

The historical rank and industry rank for iCo Therapeutics's FCF Margin % or its related term are showing as below:

ICOTF's FCF Margin % is not ranked ^*
in the Biotechnology industry.
Industry Median: -141.21
* Ranked among companies with meaningful FCF Margin % only.

iCo Therapeutics FCF Margin % Historical Data

The historical data trend for iCo Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

iCo Therapeutics FCF Margin % Chart

iCo Therapeutics Annual Data

Trend

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

FCF Margin %

Get a 7-Day Free Trial

iCo Therapeutics Quarterly Data
	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21
FCF Margin %	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of iCo Therapeutics's FCF Margin %

For the Biotechnology subindustry, iCo Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

iCo Therapeutics's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, iCo Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where iCo Therapeutics's FCF Margin % falls into.

iCo Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

iCo Therapeutics's FCF Margin for the fiscal year that ended in Dec. 2020 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2020 )	/	Revenue (A: Dec. 2020 )
	=	-0.707	/	0
	=	%

iCo Therapeutics's FCF Margin for the quarter that ended in Mar. 2021 is calculated as

FCF Margin	=	Free Cash Flow (Q: Mar. 2021 )	/	Revenue (Q: Mar. 2021 )
	=	0.215	/	0
	=	%

iCo Therapeutics FCF Margin % Related Terms

Thank you for viewing the detailed overview of iCo Therapeutics's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

iCo Therapeutics (iCo Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » iCo Therapeutics Inc (GREY:ICOTF) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

777 Hornby Street, 6th Floor, Vancouver, BC, CAN, V6Z 1S4

Website

http://www.icotherapeutics.com

iCo Therapeutics Inc is a Canada based biotechnology company. It is involved in the Research and development of ophthalmic indications. The company identifies, develops, and commercialize drug candidates with clinical history, and re-doses, reformulates and develops these drug candidates to treat sight and life-threatening diseases. Its in-licensed assets are iCo-008 and the Oral AmpB Delivery System. iCo-008 is a human monoclonal antibody targeting eotaxin-1 that acts as a messenger between the cells of the immune system. Geographically, it operates in Canada and Australia.

iCo Therapeutics (iCo Therapeutics) Headlines

No Headlines